Home › Compare › JPAVF vs ABBV
JPAVF yields 2.85% · ABBV yields 3.06%● Live data
📍 JPAVF pulled ahead of the other in Year 7
Combined, JPAVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of JPAVF + ABBV for your $10,000?
Japan Aviation Electronics Industry, Limited designs, manufactures, and sells connectors, user interface solutions, and aerospace and related electronics in Japan. The company offers input/output, board-to-board, board-to-FPC/FFC, board-to-cable, circular, rectangular, fiber optic, coaxial, cable-to-cable, memory card, memory module, high current connector, charging and discharging plug, and tool connectors; and USB, HDMI, thunderbolt, mini card, M.2 (NGFF), MXM3.0, DDR3 SODIMM, SIM card, microSD card, CompactFlash, coaxial, fiber optic, and active optical cable standard connectors. It also provides user interface solutions, such as capacitive touch panels and overlays, panel switches, teaching pendants, medical device panels, and touch panel monitors. In addition, the company offers motion sensor solutions, such as accelerometers, magnetometers, directional modules, inclinometer packages, coil for linear motor, ring lase and fiber gyro, resolver, and inertial measurement units for the aerospace, automobile mobility, railway, construction agricultural equipment, semiconductor, energy, ocean, civil engineering, and camera stabilization sectors. Its products are used in various applications, such as mobile devices, PC/digital consumer electronics/LED lighting products, infrastructure products, factory automation/robots, automotive/electrical vehicles, railway products, and medical systems. Japan Aviation Electronics Industry, Limited was incorporated in 1950 and is headquartered in Tokyo, Japan.
Full JPAVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.